LIVN logo

LIVNLivaNova PLC

$72.36
$1.36
(1.84%)
Today
Closed $72.36
$0.00
(0.00%)
After Hours
Updated: 04:16 PM EDT
EarningsAug 5
Mkt Cap$3.97B
Vol412,880.00
46

Neutral Sentiment

How do you feel about LIVN?

News
all
press releases
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Companys global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy...
Business Wire
News Placeholder
More News
News Placeholder
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
Zacks
News Placeholder
NPCE Explains How NeuroPace's RNS System Makes Money
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
Zacks
News Placeholder
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
Zacks
News Placeholder
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the...
Business Wire
News Placeholder
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir...
Business Wire
News Placeholder
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
LivaNova Q1 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported first-quarter 2026 results that management said reflected "durable performance" across its cardiopulmonary and epilepsy businesses, while also highlighting recent regulatory and clinical milestones that it believes position the company for entry into the obstructive s...
MarketBeat
News Placeholder
LivaNova (LIVN) Q2 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +15.29% and +3.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.